Company intelligence / Profile preview
Nexgen Dermatologics, Inc.
Florida, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Nexgen Dermatologics, Inc. develops novel dermatological therapies with a focus on natural and combination products. The company has sponsored at least three clinical trials targeting atopic dermatitis (ongoing as of late 2023), acne vulgaris (Phase 1/2), and senile purpura. Its approach leverages over-the-counter cosmeceuticals and oral natural extracts to address common skin conditions. There are no reported approved or commercialized drugs as of early 2025[1][7].
- Therapeutic areas
- Dermatology
- Modalities
- Natural extractsSmall moleculesCombination productsCosmeceuticals
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nexgen Dermatologics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nexgen Dermatologics, Inc..